TCGA-AQ-A04H-01B-11R-A10J-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 25
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.450
- MITOTIC_SPINDLE+0.450
- E2F_TARGETS+0.410
- TGF_BETA_SIGNALING+0.320
- PROTEIN_SECRETION+0.280
- HEME_METABOLISM+0.230
- DNA_REPAIR+0.170
- MYC_TARGETS_V1+0.160
- BILE_ACID_METABOLISM+0.150
- CHOLESTEROL_HOMEOSTASIS+0.150
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.440
- INTERFERON_GAMMA_RESPONSE-0.430
- COAGULATION-0.300
- INFLAMMATORY_RESPONSE-0.290
- PANCREAS_BETA_CELLS-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- KRAS_SIGNALING_UP-0.240
- IL6_JAK_STAT3_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-39-5040-01A-21R-2125-07 | — | cohortMD1 | 0.857 |
| 2 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.853 |
| 3 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.843 |
| 4 | TCGA-A2-A1G4-01A-11R-A13Q-07 | — | B | 0.841 |
| 5 | TCGA-AR-A2LK-01A-11R-A180-07 | — | B | 0.810 |
| 6 | TCGA-A8-A0AB-01A-11R-A034-07 | — | B | 0.807 |
| 7 | MDT-AP-3307 | Med | Medulloblastoma | 0.803 |
| 8 | TCGA-A2-A0T3-01A-21R-A115-07 | — | B | 0.803 |
| 9 | MDT-AP-0597 | Med | Medulloblastoma | 0.802 |
| 10 | MNG1222 | — | — | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |